Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PregLem: New spin in gynecology

PregLem S.A. is tackling the genitourinary and reproductive space with a mix of novel compounds and new formulations of existing products. For the former, the company thinks it should have safety and efficacy advantages. For its improved formulations, convenience is the selling proposition.

PregLem spun out of Ipsen Group in 2006 with the goal of in-licensing compounds in preclinical and clinical development and

Read the full 639 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers